The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

ICU Medical (ICUI) and Otsuka are launching a joint venture focused on boosting IV solutions production and development in North America. Read more here.

Otsuka Holdings will pay ICU Medical an upfront payment of $200 million. The U.S. IV products market has seen ...

Craig-Hallum raised the firm’s price target on BioLife Solutions (BLFS) to $32 from $30 and keeps a Buy rating on the shares. The firm notes BioLife delivered a strong Q3 update that featured a fourth ...

Lake Street analyst Thomas Flaten raised the firm’s price target on BioLife Solutions (BLFS) to $30 from $28 and keeps a Buy rating on the shares after the company reported Q3 results ahead of ...